Overview of the drug development pipeline for vasomotor symptoms of menopause
The vasomotor symptoms of menopause include night sweats and hot flashes and are described as a sudden increase in the blood flow, often to the face, neck, and chest, which causes the sensation of extreme heat and profuse sweating. Vasomotor symptoms and anxiety occur due to hormonal changes in a woman’s body, which happen post menopause. Some women face these symptoms more often due to smoking, obesity, and their ethnic background. Several public and private companies are focused on the development of drug molecules for the treatment and diagnosis of the atypical hemolytic uremic syndrome. Monotherapy is emerging as the most efficient approach for the treatment of vasomotor symptoms of menopause.
According to this pipeline analysis report, all the drug molecules in the pipeline are being developed for the treatment of vasomotor symptoms of menopause. Our market research analysts have also identified that most of these molecules are in the pre-clinical development stage and a considerable number of molecules have been discontinued from development.
Pipeline analysis report on drug development for vasomotor symptoms of menopause: Companies covered
This pipeline analysis report provides a detailed analysis of the companies that are involved in the development of drug molecules for the treatment of vasomotor symptoms of menopause. In addition to providing information on the various stages of molecules developed by companies for different indications, this pipeline analysis report also provides information about the drug molecules discontinued by companies.
Some of the companies covered in this pipeline analysis report are
- Besins Healthcare
- Endoceutics
- Fervent Pharmaceuticals
Therapeutic assessment of the drug development pipeline for vasomotor symptoms of menopause by route of administration
- Oral
- Intranasal
- Unknown
The oral route of administration (ROA) involves the administration of the drug directly into the mouth cavity, which will have a more direct effect on the target cells. The intranasal technique of ROA is administered through the nasal structure.
Therapeutic assessment of the drug development pipeline for vasomotor symptoms of menopause by therapy
- Monotherapy
- Combination Therapy
According to this pipeline analysis report, most of the molecules that are currently in the drug pipeline for vasomotor symptoms of menopause are being developed as monotherapy drugs and most of these molecules are in the pre-clinical stage of development.
Key questions answered in the report include
- What are the drug therapy molecules in the various development stages for vasomotor symptoms of menopause?
- What are the companies that are currently involved in the development of drug molecules for vasomotor symptoms of menopause?
- Insight into discontinued/inactive molecules with appropriate reasoning?
- What are the major regulatory authorities approving drugs in various regions?
- Detailed profiling of each active molecule
Technavio also offers customization on reports based on specific client requirement.